Abstract
Background: Acromegaly is a rare disease with a reported prevalence of 0.006 percent, characterized by excess growth hormone (GH) and insulin-like growth factor (IGF-1). Often leading to metabolic complications such as type 2 diabetes mellitus (T2DM). Spexin is a recently identified peptide involved in energy homeostasis and glucose metabolism. Objectives: This study aims to evaluate serum Spexin levels in acromegaly patients with and without type 2 diabetes mellitus. Materials and Methods: A total of 90 participants were enrolled, 50 patients and 40 controls who attended the Iraqi National Diabetes Center. (different in body mass index, gender, age, and diabetic status). The study parameters, such as Serum growth hormone, insulin-like growth factor-1, and fasting blood Sugar (FBS), were measured, while spexin levels were detected by enzyme-linked immunosorbent assay. This is the first study to estimate Spexin levels in patients with acromegaly. Results: Serum SPX levels were significantly higher in acromegaly patients than in controls (p=0.000). SPX levels also differed considerably across control, diabetic, and non-diabetic acromegaly groups. However, no significant correlation was found between Spexin and any other parameters included in this study. Conclusion: Elevated serum SPX levels in Iraqi patients with acromegaly suggest an involvement in disease pathophysiology; however, the underlying mechanism remains unclear, and further studies are needed to understand the potential role of SPX as a biomarker in acromegaly.

This publication has 22 references indexed in Scilit: